Angstrom6
- Generic Name
- Angstrom6
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
Phase 2
Terminated
- Conditions
- CLLChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaSLL
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Ångstrom Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02046928
- Locations
- 🇺🇸
Moores Cancer Center, UCSD, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath